Get notified when SNSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Ceo (new) — Current principal executive officer will step down upon stockholder approval, though he remains with the company as General Counsel.
- Departure Of Cfo (new) — Current principal financial officer will be replaced upon stockholder approval of the control-change proposals.
Sensei Biotherapeutics plans board overhaul and C-suite changes tied to control shift
Filed April 16, 2026 · Period ending April 10, 2026 · ~1 min read
Key Changes
-
high
Three directors to resign and three new directors to join, contingent on stockholders approving a preferred stock conversion that triggers a change of control under Nasdaq rules and increases authorized shares from 12.5M to 300M.
Item 5.02 verify on EDGAR → -
high
COO Anand Parikh will become CEO, replacing Christopher Gerry as principal executive officer. Gerry remains as General Counsel. Brian Stephenson will become CFO, replacing Josiah Craver as principal financial officer.
Item 5.02 verify on EDGAR → -
medium
Board adopted new severance plan offering executives 6-12 months salary for normal terminations, or enhanced packages (12-18 months salary, 1.0x-1.5x bonus, full equity acceleration) for change-of-control terminations.
Item 5.02 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade SNSE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify